CD19-7×19 CAR-T(Ningbo No. 1 Hospital)(CD19-7×19 CAR-T(Ningbo No. 1 Hospital))

概要

基本信息

药物类型

CAR-T

别名

CD19 CAR-T Expressing IL-7 and CCL19(Ningbo No. 1 Hospital)

靶点

CD19

作用机制

CD19调节剂(B淋巴细胞抗原CD19调节剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域-

在研适应症-

非在研适应症-

原研机构

宁波市第一医院

在研机构

宁波市第一医院

浙江大学

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

1

项与 CD19-7×19 CAR-T(Ningbo No. 1 Hospital) 相关的临床试验

NCT05659628 / Recruiting临床1期IIT

Phase Ib Clinical Study of CD19 CAR-T Expressing IL-7 and CCL19 Combined With Tislelizumab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

The goal of this clinical trial is to test CD19-7×19 CAR-T cells combined with Tislelizumab in refractory and relapsed diffuse large B lymphoma. The main question[s] it aims to answer are:
question 1：What is the safety of CD19-7×19 CAR-T cells combined with Tislelizumab in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
question 2：What is the efficacy of CD19-7×19 CAR-T cells combined with Tislelizumab in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Participants will be asked to receive clinical evaluation before CAR-T, including physical examination, blood routine test, biochemical test, imaging test, etc.Peripheral blood lymphocytes will be collected for preparation of CAR-T cells after enrollment. Pretreatment chemotherapy with fludarabine and cyclophosphamide will be used before CAR-T infusion. On the 31st day after CAR-T infusion, Tislelizumab 200mg was given once every 21 days for 6 cycles. Participants will be required to report concomitant medication and adverse events, and their disease was evaluated throughout the study.

开始日期2022-12-01

申办/合作机构